|
AP7401a-ev
|
Abcepta, Inc.
|
CHK1 [C-term] [RB2529], Rabbit Polyclonal Antibody
|
Human, Mouse
|
WB
|
|
|
AP7401a
|
Abcepta, Inc.
|
CHK1 [C-term] [RB2529], Rabbit Polyclonal Antibody
|
Human, Mouse
|
WB
|
|
|
AP3070a-ev
|
Abcepta, Inc.
|
p-CHK1 [Ser317] [RB7845, RB18425], Rabbit Polyclonal Antibody
|
Human
|
IHC-P, WB, DB
|
|
|
AP3070a
|
Abcepta, Inc.
|
p-CHK1 [Ser317] [RB7845, RB18425], Rabbit Polyclonal Antibody
|
Human
|
IHC-P, WB, DB
|
|
|
ATGP3467-20ug
|
NKMax Bio (ATGen)
|
Carboxylesterase 3/CES3 [19-565 a.a.], Recombinant Protein
|
Mouse
|
Enzyme Activity, SDS-PAGE
|
|
|
ATGP3683-10ug
|
NKMax Bio (ATGen)
|
CDK5 [1-292 a.a.], Recombinant Protein
|
Human
|
SDS-PAGE
|
|
|
ATGP3683-50ug
|
NKMax Bio (ATGen)
|
CDK5 [1-292 a.a.], Recombinant Protein
|
Human
|
SDS-PAGE
|
|
|
HY-13057-10mg
|
MedChemexpress LLC
|
O6BTG-octylglucoside [CAS 382607-78-5]
|
|
Cancer-programmed cell death
|
|
|
HY-13057-100mg
|
MedChemexpress LLC
|
O6BTG-octylglucoside [CAS 382607-78-5]
|
|
Cancer-programmed cell death
|
|
|
HY-13057-5mg
|
MedChemexpress LLC
|
O6BTG-octylglucoside [CAS 382607-78-5]
|
|
Cancer-programmed cell death
|
|
|
HY-13057-50mg
|
MedChemexpress LLC
|
O6BTG-octylglucoside [CAS 382607-78-5]
|
|
Cancer-programmed cell death
|
|
|
HY-13057-1mL
|
MedChemexpress LLC
|
O6BTG-octylglucoside [CAS 382607-78-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-112100-10mg
|
MedChemexpress LLC
|
PAC [CAS 2158322-33-7]
|
|
Cancer-programmed cell death
|
|
|
HY-112100-5mg
|
MedChemexpress LLC
|
PAC [CAS 2158322-33-7]
|
|
Cancer-programmed cell death
|
|
|
HY-115627-1mg
|
MedChemexpress LLC
|
PKUMDL-LC-101-D04 [CAS 2143896-83-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-115627-10mg
|
MedChemexpress LLC
|
PKUMDL-LC-101-D04 [CAS 2143896-83-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-115627-25mg
|
MedChemexpress LLC
|
PKUMDL-LC-101-D04 [CAS 2143896-83-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-115627-5mg
|
MedChemexpress LLC
|
PKUMDL-LC-101-D04 [CAS 2143896-83-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-115627-50mg
|
MedChemexpress LLC
|
PKUMDL-LC-101-D04 [CAS 2143896-83-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-112098-10mg
|
MedChemexpress LLC
|
PROTAC ERAlpha Degrader-1 [CAS 2417369-94-7]
|
|
Cancer-programmed cell death
|
|
|
HY-112098-2mg
|
MedChemexpress LLC
|
PROTAC ERAlpha Degrader-1 [CAS 2417369-94-7]
|
|
Cancer-programmed cell death
|
|
|
HY-112098-25mg
|
MedChemexpress LLC
|
PROTAC ERAlpha Degrader-1 [CAS 2417369-94-7]
|
|
Cancer-programmed cell death
|
|
|
HY-112098-5mg
|
MedChemexpress LLC
|
PROTAC ERAlpha Degrader-1 [CAS 2417369-94-7]
|
|
Cancer-programmed cell death
|
|
|
HY-112098-50mg
|
MedChemexpress LLC
|
PROTAC ERAlpha Degrader-1 [CAS 2417369-94-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13749B-100mg
|
MedChemexpress LLC
|
Sitagliptin (phosphate monohydrate) [CAS 654671-77-9]
|
|
Metabolism-protein/nucleotide metabolism
|
|
